• Je něco špatně v tomto záznamu ?

Inhibition of soluble epoxide hydrolase counteracts the development of renal dysfunction and progression of congestive heart failure in Ren-2 transgenic hypertensive rats with aorto-caval fistula

L. Červenka, V. Melenovský, Z. Husková, P. Škaroupková, A. Nishiyama, J. Sadowski,

. 2015 ; 42 (7) : 795-807.

Jazyk angličtina Země Austrálie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16010203

Grantová podpora
NT14050 MZ0 CEP - Centrální evidence projektů
NT14012 MZ0 CEP - Centrální evidence projektů

The detailed mechanisms determining the course of congestive heart failure (CHF) in hypertensive subjects with associated renal dysfunction remain unclear. In Ren-2 transgenic rats (TGR), a model of angiotensin II (ANG II)-dependent hypertension, CHF was induced by volume overload achieved by creation of the aorto-caval fistula (ACF). In these rats we investigated the putative pathophysiological contribution of epoxyeicosatrienoic acids (EETs) and compared it with the role of the renin-angiotensin system (RAS). We found that untreated ACF TGR exhibited marked intrarenal and myocardial deficiency of EETs and impairment of renal function. Chronic treatment of these rats with cis-4-[4-(3-adamantan-1-yl-ureido)cyclohexyloxy]benzoic acid (c-AUCB, 3 mg/L in drinking water), an inhibitor of soluble epoxide hydrolase (sEH) which normally degrades EETs, increased intrarenal and myocardial EETs, markedly improved survival rate, and increased renal blood flow, glomerular filtration rate and fractional sodium excretion, without altering RAS activity. Chronic angiotensin-converting enzyme inhibition (ACEi) with trandolapril, (6 mg/L in drinking water) improved survival rate even more, and also inhibited the development of renal dysfunction; these beneficial actions were associated with significant suppression of the vasoconstrictor/sodium retaining axis and further activation of the vasodilatory/natriuretic axis of the systemic and intrarenal RAS, without modifying tissue availability of biologically active fatty acid epoxides. In conclusion, these findings strongly suggest that chronic sEH inhibition and chronic treatment with ACEi, each of them altering a different vasoactive system, delay or even prevent the onset of decompensation of CHF in ACF TGR, probably by preventing the development of renal dysfunction.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16010203
003      
CZ-PrNML
005      
20191108133917.0
007      
ta
008      
160408s2015 at f 000 0|eng||
009      
AR
024    7_
$a 10.1111/1440-1681.12419 $2 doi
024    7_
$a 10.1111/1440-1681.12419 $2 doi
035    __
$a (PubMed)25969338
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a at
100    1_
$a Červenka, Luděk, $u Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. Department of Pathophysiology, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic. $d 1967- $7 xx0037105
245    10
$a Inhibition of soluble epoxide hydrolase counteracts the development of renal dysfunction and progression of congestive heart failure in Ren-2 transgenic hypertensive rats with aorto-caval fistula / $c L. Červenka, V. Melenovský, Z. Husková, P. Škaroupková, A. Nishiyama, J. Sadowski,
520    9_
$a The detailed mechanisms determining the course of congestive heart failure (CHF) in hypertensive subjects with associated renal dysfunction remain unclear. In Ren-2 transgenic rats (TGR), a model of angiotensin II (ANG II)-dependent hypertension, CHF was induced by volume overload achieved by creation of the aorto-caval fistula (ACF). In these rats we investigated the putative pathophysiological contribution of epoxyeicosatrienoic acids (EETs) and compared it with the role of the renin-angiotensin system (RAS). We found that untreated ACF TGR exhibited marked intrarenal and myocardial deficiency of EETs and impairment of renal function. Chronic treatment of these rats with cis-4-[4-(3-adamantan-1-yl-ureido)cyclohexyloxy]benzoic acid (c-AUCB, 3 mg/L in drinking water), an inhibitor of soluble epoxide hydrolase (sEH) which normally degrades EETs, increased intrarenal and myocardial EETs, markedly improved survival rate, and increased renal blood flow, glomerular filtration rate and fractional sodium excretion, without altering RAS activity. Chronic angiotensin-converting enzyme inhibition (ACEi) with trandolapril, (6 mg/L in drinking water) improved survival rate even more, and also inhibited the development of renal dysfunction; these beneficial actions were associated with significant suppression of the vasoconstrictor/sodium retaining axis and further activation of the vasodilatory/natriuretic axis of the systemic and intrarenal RAS, without modifying tissue availability of biologically active fatty acid epoxides. In conclusion, these findings strongly suggest that chronic sEH inhibition and chronic treatment with ACEi, each of them altering a different vasoactive system, delay or even prevent the onset of decompensation of CHF in ACF TGR, probably by preventing the development of renal dysfunction.
650    _2
$a angiotensin I $x metabolismus $7 D000803
650    _2
$a angiotensin II $x metabolismus $7 D000804
650    _2
$a inhibitory ACE $x farmakologie $x terapeutické užití $7 D000806
650    _2
$a zvířata $7 D000818
650    _2
$a aorta $7 D001011
650    _2
$a krevní tlak $x účinky léků $7 D001794
650    _2
$a systém (enzymů) cytochromů P-450 $x metabolismus $7 D003577
650    12
$a progrese nemoci $7 D018450
650    _2
$a inhibitory enzymů $x farmakologie $x terapeutické užití $7 D004791
650    _2
$a epoxid hydrolasy $x antagonisté a inhibitory $x chemie $7 D004851
650    _2
$a kyseliny mastné mononenasycené $x metabolismus $7 D005229
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a píštěle $x komplikace $7 D005402
650    _2
$a srdeční selhání $x farmakoterapie $x etiologie $x patofyziologie $7 D006333
650    _2
$a srdeční frekvence $x účinky léků $7 D006339
650    _2
$a hemodynamika $x účinky léků $7 D006439
650    _2
$a ledviny $x účinky léků $x patofyziologie $7 D007668
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a peptidové fragmenty $x metabolismus $7 D010446
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani transgenní $7 D055647
650    _2
$a renin $x genetika $7 D012083
650    _2
$a renin-angiotensin systém $x účinky léků $7 D012084
650    _2
$a rozpustnost $7 D012995
650    _2
$a časové faktory $7 D013997
650    _2
$a vena cava inferior $7 D014682
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Melenovský, Vojtěch $u Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. $7 xx0160847
700    1_
$a Husková, Zuzana, $u Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. $d 1978- $7 xx0074206
700    1_
$a Škaroupková, Petra $u Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. $7 xx0117683
700    1_
$a Nishiyama, Akira $u Department of Pharmacology, Kagawa University, Kagawa, Japan.
700    1_
$a Sadowski, Janusz $u Department of Renal and Body Fluid Physiology, M. Mossakowski Medical Research Centre, Polish Academy of Science, Warsaw, Poland.
773    0_
$w MED00007158 $t Clinical and experimental pharmacology & physiology $x 1440-1681 $g Roč. 42, č. 7 (2015), s. 795-807
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25969338 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20191108134149 $b ABA008
999    __
$a ok $b bmc $g 1113632 $s 934571
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 42 $c 7 $d 795-807 $i 1440-1681 $m Clinical and experimental pharmacology & physiology $n Clin Exp Pharmacol Physiol $x MED00007158
GRA    __
$a NT14050 $p MZ0
GRA    __
$a NT14012 $p MZ0
LZP    __
$a Pubmed-20160408

Najít záznam

Citační ukazatele

Možnosti archivace